Business
Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022
SAN DIEGO, June 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presents data on sleep disturbances in Parkinson's disease (PD)
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, June 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presents data on sleep disturbances in Parkinson's disease (PD) demonstrating the impact of OFF episodes, or reemergence of symptoms between doses of levodopa, on falling asleep and staying asleep. These data (abstract ID: 0581) are being shared at SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies, LLC (APSS) being held June 4-8 in Charlotte, North Carolina. The oral presentation of these data will take place on June 8 at 2:15 p.m. (oral presentation session: O-28).\n\n \n \n \n \n \n \n\n \n\"Sleep disturbances in individuals with Parkinson's disease can significantly impact health, mood, and quality of life,\" said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. \"These data provide insight on the impact of OFF episodes and their contribution to sleep disturbances, both in falling asleep and staying asleep. At Neurocrine Biosciences, we are committed to furthering understanding of the wide-ranging effects of movement disorders to elevate care for the patients we serve.\"\nThe post-hoc analyses were conducted using baseline data from two previous Phase 3 studies of ONGENTYS® (opicapone) capsules, an approved once-daily adjunctive treatment to levodopa/carbidopa (LD/CD) in patients with PD experiencing OFF time. \nResults of this post-hoc analysis indicate that 34.4% (332/964) of participants experienced an OFF episode before going to sleep for a mean duration of 1.8±1.2 hours. Among participants who woke up during the night (16.4%, 158/964), 81.0% (128/158) were in an OFF state for a mean duration of 1.0 (±0.5) hours. Additionally, 89.4% (898/1005) of participants experienced an OFF episode upon waking in the morning, with the mean duration of this time to morning \"ON\" episode being 1.5 (±0.9) hours. OFF episodes can contribute to sleep impairment, a common but poorly addressed problem in patients with PD. The potential impact of OFF periods on sleep has not been well characterized.\nAbout ONGENTYS® (opicapone) Capsules ONGENTYS is a once-daily, oral, peripheral, selective and reversible catechol-O-methyltransferase (COMT) inhibitor approved by the U.S. Food and Drug Administration (FDA) as an add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing \"OFF...